Glenmark Pharmaceuticals Inc., USA launched Axitinib tablets in 1 mg and 5 mg strengths as an authorized generic version of Pfizer's Inlyta in the United States.
The targeted oral oncology medication is prescribed to treat advanced renal cell carcinoma, a common type of kidney cancer.
According to IQVIA data for the 12 months ended September 2026, Inlyta tablets generated approximately $538.4 million in annual US sales.